Immune microenvironment composition in non‐small cell lung cancer and its association with survival

Link to paper Tamminga M, Hilterman TJN, Schuuring E, Timens W, Fehrmann RSN, Groen HJM. Abstract Objectives In non‐small cell lung cancer (NSCLC), the immune system and possibly its composition affect survival. In this in silico study, the immune infiltrate composition in NSCLC patients was evaluated. Methods Gene expression data of tumors from early NSCLC patients were…

Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

link to paper Hanemaaijer S, Kok I, Fehrmann RSN, van der Vegt B, Gietema J, Plaat B, van Vugt MATM, Vergeer M, Leemans RC, Langendijk JA, Voortman J, Buter J, Oosting JF. Background: Chemoradiotherapy (CRT) including three cycles of cisplatin is considered the standard of care for locally advanced head and neck squamous cell carcinoma…

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer

Link to paper Workel HH, van Rooij N, Plat A, Spierings DCJ, Fehrmann RSN, Nijman HW. de Bruyn M Abstract: Tumor-infiltrating CD8+ T cells (TIL) are of the utmost importance in anti-tumor immunity. CD103 defines tumor-resident memory T cells (TRM cells) associated with improved survival and response to immune checkpoint blockade (ICB) across human tumors. Co-expression…

Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?

Link to paper Knapen DJ, Kwee TC, Meijne EIM, Fehrmann RSN, de Vries EGE AbstractImmune checkpoint inhibitors (ICI) have improved outcomes for patients with advanced cancers, and results in increasing numbers of long-term survivors. For registration studies, progression-free survival and disease-free survival often serve as primary endpoints. This requires repeated computed tomography (CT) scans for…

Transcriptional effects of copy number alterations in a large set of human cancers

Link to paper Bhattacharya A, Bense RD, Urzúa-Traslaviña CG, de Vries EGE, van Vugt MATM, Fehrmann RSN AbstractCopy number alterations (CNAs) can promote tumor progression by altering gene expression levels. Due to transcriptional adaptive mechanisms, however, CNAs do not always translate proportionally into altered expression levels. By reanalyzing >34,000 gene expression profiles, we reveal the…

Driving innovation for rare skin cancers: utilising common tumours and machine learning to predict immune checkpoint inhibitor response

Link to paper J.S. Hooiveld-Noeken, R.S.N. Fehrmann, E.G.E. de Vries, M. Jalving Highlights • Metastatic Merkel- and cutaneous squamous cell carcinoma are rare tumours. • Immunotherapy gives impressive responses but most patients do not survive long-term. • Small patients numbers prevent extensive biomarker research in clinical trials. • Pooled data from common and rare tumours…

Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers

Link to paper Peters MAM, Meijer C, Fehrmann RSN, Walenkamp AME, Kema IP, de Vries EGE, Hollema H, Oosting SF. Abstract In preclinical studies serotonin stimulates and dopamine inhibits tumour growth and angiogenesis. Information regarding serotonin and dopamine receptor (5-HTR and DRD) expression in human cancers is limited. Therefore, we screened a large tumour set…

CD47 expression defines efficacy of rituximab with CHOP in Non-Germinal Center B-cell (non-GCB) Diffuse Large B-Cell Lymphoma patients (DLBCL), but not in GCB DLBCL

Link to paper Bouwstra R, He Y, de Boer JW, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T. Abstract Addition of rituximab (R) to “CHOP” (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients that…